FY2022 Q3 Financial and R&D Update

Major R&D Milestones (Alpha) Project Quizartinib TARLIGE® (mirogabalin) DS-1211 • DS-5670 Target Indication [phase, study name] . AML, 1L [Ph3, JP/US/EU/Asia] • DPNP • . PXE [Ph2, US/EU] • COVID-19 mRNA vaccine (original strain), booster vaccination [Ph1/2/3, JP] COVID-19 mRNA vaccine (original strain), primary vaccination [Ph3, JP] As of Jan 2023 FY2022 H2 FY2023 H1 H2 • Approval Approval Filing accepted (US) anticipated (JP/US) anticipated (EU) • Filing accepted • (China) Study Started . • TLR obtained • Filing accepted (JP) TLR anticipated • Study start anticipated . COVID-19 mRNA vaccine (BA.4-5), vaccination [Ph3, JP] FLUMISTⓇ (VN-0107) • Nasal seasonal influenza vaccine [JP] • Approval anticipated (JP) Bold: update from FY2022 Q2 AML: acute myeloid leukemia, DPNP: diabetic peripheral neuropathic pain, PXE: pseudoxanthoma elasticum, TLR: Top Line Results Timeline indicated is based on the current forecast and subject to change Daiichi-Sankyo 36

View entire presentation